Predictors of 5-Year Mortality in Patients Managed With a Magnetically Levitated Left Ventricular Assist Device.
Aditi NayakShelley A HallNir UrielDaniel J GoldsteinJoseph C ClevelandJennifer A CowgerChristopher T SalernoYoshifumi NakaDouglas HorstmanshofDaniel CrandallAiJia WangMandeep R MehraPublished in: Journal of the American College of Cardiology (2023)
Long-term survival in successfully discharged HM3 LVAD recipients is largely influenced by clinical events experienced during the index surgical hospitalization in tandem with baseline factors, with mortality of <50% at 5 years. In patients without identified predictors of risk, long-term 5-year mortality is low and rivals that achieved with heart transplantation, even though most were implanted with destination therapy intent. (MOMENTUM 3 IDE Clinical Study Protocol, NCT02224755; MOMENTUM 3 Pivotal Cohort Extended Follow-up PAS, NCT03982979).
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- left ventricular assist device
- study protocol
- randomized controlled trial
- cardiovascular events
- prognostic factors
- peritoneal dialysis
- type diabetes
- stem cells
- patient reported outcomes
- patient reported
- bone marrow
- open label
- smoking cessation